FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2071644815> ?p ?o ?g. }

• W2071644815 endingPage "580" @default.
• W2071644815 startingPage "572" @default.
• W2071644815 abstract "The poor prognosis for elderly patients with acute myeloid leukemia (AML) raises questions regarding the benefit of treating them with intensive chemotherapy. The impact of initial characteristics on prognosis has been addressed previously in elderly patients; however, very few data are available regarding the prognostic value of immunophenotypic characteristics in this setting.The authors investigated expression of the membrane antigens CD13, CD15, CD33, and CD34 by flow cytometry in elderly patients with newly diagnosed AML and analyzed whether these parameters had clinical or prognostic relevance to help physicians in their choice of therapy.Immunophenotyping was performed in 273 patients aged > or =60 years (median age, 69 years). CD13 was expressed in 73% of patients, CD15 was expressed in 43% of patients, CD33 was expressed in 64% of patients, and CD34 was expressed in 66% of patients. Complete remission was obtained in 157 patients (58%). The median overall survival was 8.1 months, and the 3-year survival rate was 14%. Three risk groups were defined based on CD34 and CD33 antigen expression: The poor-risk group included patients with CD34-positive/CD33-positive or CD34-negative/CD33-negative disease, the intermediate-risk group included patients with CD34-positive/CD33-negative disease, and the favorable-risk group included patients with CD34-negative/CD33-positive disease. After cytogenetic analyses, immunophenotype was the most significant prognostic factor in terms of survival in a multivariate analysis (P = .03 and P < .0001, respectively). When immunophenotypic and cytogenetic parameters were combined, patients were classified into 4 prognostic groups: Group A (3-year survival rate, 33%) included patients with favorable and normal karyotypes who had a favorable immunophenotype, Group B (3-year survival rte, 28%) included patients with normal karyotypes who had an intermediate immunophenotype, Group C (3-year survival rate, 8%) included patients with intermediate or normal karyotypes who had an unfavorable immunophenotype, and Group D (3-year survival rate, 2%) included all patients who had unfavorable cytogenetics.Immunophenotypic characteristics appeared to be a major prognostic factor in this population of elderly patients with AML. By using 2 simple parameters assessed at the time of diagnosis, the authors devised a prognostic system of immediate clinical utility for prognostic stratification and risk-adapted therapeutic choices." @default.
• W2071644815 created "2016-06-24" @default.
• W2071644815 creator A5006793451 @default.
• W2071644815 creator A5014257321 @default.
• W2071644815 creator A5028508696 @default.
• W2071644815 creator A5045792540 @default.
• W2071644815 creator A5052966035 @default.
• W2071644815 creator A5072027146 @default.
• W2071644815 creator A5077614586 @default.
• W2071644815 creator A5078817313 @default.
• W2071644815 date "2008-02-01" @default.
• W2071644815 modified "2023-10-03" @default.
• W2071644815 title "Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia" @default.
• W2071644815 cites W1556454749 @default.
• W2071644815 cites W1562680005 @default.
• W2071644815 cites W1919339218 @default.
• W2071644815 cites W1963335440 @default.
• W2071644815 cites W2005157480 @default.
• W2071644815 cites W2028521588 @default.
• W2071644815 cites W2028845178 @default.
• W2071644815 cites W2034295250 @default.
• W2071644815 cites W2034409643 @default.
• W2071644815 cites W2039082386 @default.
• W2071644815 cites W2041562149 @default.
• W2071644815 cites W2045911327 @default.
• W2071644815 cites W2046185040 @default.
• W2071644815 cites W2051992463 @default.
• W2071644815 cites W2075808651 @default.
• W2071644815 cites W2078090409 @default.
• W2071644815 cites W2090076603 @default.
• W2071644815 cites W2111121001 @default.
• W2071644815 cites W2142036452 @default.
• W2071644815 cites W2142586916 @default.
• W2071644815 cites W2148855592 @default.
• W2071644815 cites W2150113701 @default.
• W2071644815 cites W2158171581 @default.
• W2071644815 cites W2159738043 @default.
• W2071644815 cites W2162700652 @default.
• W2071644815 cites W2325817309 @default.
• W2071644815 cites W2325902709 @default.
• W2071644815 cites W2764775166 @default.
• W2071644815 cites W3111770416 @default.
• W2071644815 cites W4244897830 @default.
• W2071644815 cites W86828079 @default.
• W2071644815 doi "https://doi.org/10.1002/cncr.23219" @default.
• W2071644815 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18085638" @default.
• W2071644815 hasPublicationYear "2008" @default.
• W2071644815 type Work @default.
• W2071644815 sameAs 2071644815 @default.
• W2071644815 citedByCount "46" @default.
• W2071644815 countsByYear W20716448152012 @default.
• W2071644815 countsByYear W20716448152013 @default.
• W2071644815 countsByYear W20716448152014 @default.
• W2071644815 countsByYear W20716448152015 @default.
• W2071644815 countsByYear W20716448152016 @default.
• W2071644815 countsByYear W20716448152017 @default.
• W2071644815 countsByYear W20716448152018 @default.
• W2071644815 countsByYear W20716448152021 @default.
• W2071644815 countsByYear W20716448152022 @default.
• W2071644815 countsByYear W20716448152023 @default.
• W2071644815 crossrefType "journal-article" @default.
• W2071644815 hasAuthorship W2071644815A5006793451 @default.
• W2071644815 hasAuthorship W2071644815A5014257321 @default.
• W2071644815 hasAuthorship W2071644815A5028508696 @default.
• W2071644815 hasAuthorship W2071644815A5045792540 @default.
• W2071644815 hasAuthorship W2071644815A5052966035 @default.
• W2071644815 hasAuthorship W2071644815A5072027146 @default.
• W2071644815 hasAuthorship W2071644815A5077614586 @default.
• W2071644815 hasAuthorship W2071644815A5078817313 @default.
• W2071644815 hasBestOaLocation W20716448151 @default.
• W2071644815 hasConcept C10205521 @default.
• W2071644815 hasConcept C126322002 @default.
• W2071644815 hasConcept C143998085 @default.
• W2071644815 hasConcept C147483822 @default.
• W2071644815 hasConcept C176290653 @default.
• W2071644815 hasConcept C196166836 @default.
• W2071644815 hasConcept C203014093 @default.
• W2071644815 hasConcept C2776804306 @default.
• W2071644815 hasConcept C2778729363 @default.
• W2071644815 hasConcept C28328180 @default.
• W2071644815 hasConcept C54355233 @default.
• W2071644815 hasConcept C71924100 @default.
• W2071644815 hasConcept C86803240 @default.
• W2071644815 hasConcept C90924648 @default.
• W2071644815 hasConceptScore W2071644815C10205521 @default.
• W2071644815 hasConceptScore W2071644815C126322002 @default.
• W2071644815 hasConceptScore W2071644815C143998085 @default.
• W2071644815 hasConceptScore W2071644815C147483822 @default.
• W2071644815 hasConceptScore W2071644815C176290653 @default.
• W2071644815 hasConceptScore W2071644815C196166836 @default.
• W2071644815 hasConceptScore W2071644815C203014093 @default.
• W2071644815 hasConceptScore W2071644815C2776804306 @default.
• W2071644815 hasConceptScore W2071644815C2778729363 @default.
• W2071644815 hasConceptScore W2071644815C28328180 @default.
• W2071644815 hasConceptScore W2071644815C54355233 @default.
• W2071644815 hasConceptScore W2071644815C71924100 @default.
• W2071644815 hasConceptScore W2071644815C86803240 @default.
• W2071644815 hasConceptScore W2071644815C90924648 @default.

• next